Home
About Us
Company Profile
Core Team
Corporate Culture
Development Path
Technology Platform
Platform Technology Advantages
Bispecific Antibody Platform
Platform Advantages
Product Differentiation
R&D Pipeline
News
Contact Us
Contact Us
Recruitment
EN
CN
News
Focus on the early discovery and clinical development of bispecific antibody and ADC.
/
Successful Completion of $42M Series A Financing to Accelerate Global Development of Bispecific Antibody and ADC Pipeline
/
U.S. FDA IND Clearance and First Patient Dosed in Australia for First Oncology ADC Program ALK201